Vesper Biotechnologies ApS
🇩🇰Denmark
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Vesper Biotechnologies ApS
- Target Recruit Count
- 78
- Registration Number
- NCT06226064
- Locations
- 🇳🇱
Center for Human Drug Research, Leiden, Netherlands
© Copyright 2025. All Rights Reserved by MedPath